Summary:
CL04041023 A Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis inadequately Controlled by Methotrexate Therapy
Qualified Participants May Receive:
Patient that qualify will receive free study treatment, Laboratory results, clinic visits, $50.00 per visit completed if qualified for the study.